Drug intelligence / Profile preview

deoxyribonuclease I

Development stage
Approved
Lead developer
Genentech
Modality
Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration
Inhalation
01

Overview

Deoxyribonuclease I (DNase I) is an endonuclease enzyme that cleaves DNA by hydrolyzing phosphodiester bonds adjacent to pyrimidine nucleotides, producing oligonucleotides with terminal 5'-phosphates and 3'-hydroxyl groups. It acts on both single- and double-stranded DNA as well as chromatin. The enzyme requires divalent cations (such as Mg²⁺ or Ca²⁺) for activity and is found naturally in human saliva, urine, pancreatic secretions, and blood. Recombinant human DNase I (dornase alfa; brand name Pulmozyme) is used therapeutically to reduce the viscosity of sputum in patients with cystic fibrosis by digesting extracellular DNA in airway secretions. DNase I has also been investigated for use in respiratory failure associated with COVID-19. Mutations or deficiencies in DNASE1 are linked to autoimmune diseases such as systemic lupus erythematosus[2][5][6][8].

Brand names
Pulmozymedornase alfa
Other names
Deoxyribonuclease ADeoxyribonucleate 5'-oligonucleotidohydrolase
02

Targets

cfDNA (Cell-free DNA)

Beyond the preview

Go deeper on deoxyribonuclease I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on deoxyribonuclease I.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call